WO2002085853A2 - Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands - Google Patents

Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands Download PDF

Info

Publication number
WO2002085853A2
WO2002085853A2 PCT/US2002/012512 US0212512W WO02085853A2 WO 2002085853 A2 WO2002085853 A2 WO 2002085853A2 US 0212512 W US0212512 W US 0212512W WO 02085853 A2 WO02085853 A2 WO 02085853A2
Authority
WO
WIPO (PCT)
Prior art keywords
ylmethoxy
sulfonyl
formula
optionally substituted
compound
Prior art date
Application number
PCT/US2002/012512
Other languages
French (fr)
Other versions
WO2002085853A3 (en
Inventor
Yanfang Li
Ping Zhou
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200301143A priority Critical patent/EA200301143A1/en
Application filed by Wyeth filed Critical Wyeth
Priority to CA002444036A priority patent/CA2444036A1/en
Priority to BR0209047-3A priority patent/BR0209047A/en
Priority to KR10-2003-7013584A priority patent/KR20030088507A/en
Priority to EP02736592A priority patent/EP1392682A2/en
Priority to HU0303801A priority patent/HUP0303801A2/en
Priority to IL15844802A priority patent/IL158448A0/en
Priority to AU2002309585A priority patent/AU2002309585B2/en
Priority to MXPA03009490A priority patent/MXPA03009490A/en
Priority to JP2002583380A priority patent/JP2004526781A/en
Publication of WO2002085853A2 publication Critical patent/WO2002085853A2/en
Publication of WO2002085853A3 publication Critical patent/WO2002085853A3/en
Priority to NO20034647A priority patent/NO20034647L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • This invention relates to heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5- hydroxytryptamine-6 ligands, to processes for preparing them, to methods of using them and to pharmaceutical compositions containing them.
  • 5-HT neurotransmitter 5- hydroxytryptamine
  • serotonin is localized in the central and peripheral nervous systems and is known to affect many types of conditions including psychiatric disorders, motor activity, feeding behavior, sexual activity, and neuroendocrine regulation among others.
  • the effects of serotonin are regulated by the various 5-HT receptor subtypes.
  • 5-HT receptors include the 5-HTl family (e.g. 5-HTlA) , the 5-HT2 family (e.g. 5-HT2A) , 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 subtypes .
  • 5-HT6 receptor subtype The recently identified human 5-hydroxytryptamine-6 (5-HT6) receptor subtype has been cloned, and the extensive distribution of its mRNA has been reported. Highest levels of 5-HT6 receptor mRNA have been observed in the olfactory tubercle, the striatum, nucleus accumbens, dentate gyrus and CAl, CA2 and CA3 regions of the hippocampus. Lower levels of 5-HT6 receptor mRNA were seen in the granular layer of the cerebellum, several diencephalic nuclei, amygdala and in the cortex. Northern blots have revealed that 5-HT6 receptor mRNA appears to be exclusively present in the brain, with little evidence for its presence in peripheral tissues.
  • 5-HT6 receptor ligands are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding disorders (e.g. anorexia and bulimia), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine and benzodiazepines) , schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome.
  • the present invention provides a compound of formula
  • X is 0, SO y or NR 13 ; Y is CR 14 or N;
  • Z is CR 15 or N with the proviso that when Y is N then Z must be CR 15 ; m and x are each independently 0 or an integer of 1,
  • n and p are each independently an integer of 1, 2 or 3; n and p are each independently an integer of 1, 2 or
  • R 1 is halogen, CN, 0R 16 , C0 2 R 17 , CONR 18 R 19 , CNR 20 NR 21 R 22 , S0 2 NR 23 R 21 , SO w R 25 , or a C.-C ⁇ lkyl, C 2 -C 6 alkenyl , C 2 -
  • R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 1X are each independently H or an optionally substituted C x - C 6 alkyl group;
  • R is H, CNR 26 NR 27 R 28 or a C.,-C 6 alkyl, C 2 -C 6 alkenyl , C 2 - C 6 alkynyl, C 3 -C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
  • R 12 is an optionally substituted C.-C 6 alkyl, aryl or heteroaryl grou ;
  • y and w are each 0 or an integer of 1 or 2 ;
  • R 13 is H or a C--C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl , C 3 - C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
  • R 14 and R 15 are each independently H, halogen or a C ⁇ - C 6 alkyl, aryl, heteroaryl or C--C 6 alkoxy group each optionally substituted;
  • R 16 is H, COR 29 or a C.-C 6 alkyl, C 2 -C 6 alkenyl , C 2 - C 6 alkynyl, aryl or heteroaryl group each optionally substituted;
  • R 17 and R 29 are each independently H or a C..-C 6 alkyl,
  • R 23 and R 24 are each independently H or a C--C 6 alkyl, aryl or heteroaryl group each optionally substituted; and R 25 is an optionally substituted C.,-C 6 alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
  • the present invention also provides methods and compositions useful for the therapeutic treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
  • the present invention further provides a method for the preparation of compounds of formula I and a compound useful therefor.
  • the 5-hydroxytryptamine-6 (5-HT6) receptor is one of the most recent receptors to be identified by molecular cloning. Its ability to bind a wide range of therapeutic compounds used in psychiatry, coupled with its intriguing distribution in the brain has stimulated significant interest in new compounds which are capable of interacting with or affecting said receptor. At present, there are no known fully selective agonists. Significant efforts are being made to understand the possible role of the 5-HT6 receptor in psychiatry, cognitive dysfunction, motor function and control, memory, mood and the like. To that end, compounds which demonstrate a binding affinity for the 5-HT6 receptor are earnestly sought both as an aid in the study of the 5-HT6 receptor and as potential therapeutic agents in the treatment of central nervous system disorders.
  • heterocyclylalkoxy-, -thioxy- or -aminobenzazole derivatives of formula I demonstrate 5-HT6 affinity.
  • said benzazole derivatives may be used as effective therapeutic agents for the treatment of central nervous system (CNS) disorders associated with or affected by the 5-HT6 receptor.
  • CNS central nervous system
  • the present invention provides heterocyclylalkoxy-, -alkylthio- or -alkylaminobenzazole derivatives of formula I
  • W is S0 2 , CO, CONH, CSNH or (CH 2 ) x ;
  • X is 0, SO y or NR 13 ;
  • Y is CR M or N;
  • Z is CR 1S or N with the proviso that when Y is N then
  • Z must be CR 1S ; m and x are each independently 0 or an integer of 1, 2 or 3; n and p are each independently an integer of 1, 2 or
  • R. is halogen, CN, OR 16 , C0 2 R 17 , CONR 18 R 19 , CNR 20 NR 21 R 22 ,
  • R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R u are each independently H or an optionally substituted C- C 6 alkyl group;
  • R 4 is H, CNR 26 NR 27 R 28 or a C--C 6 alkyl, C 2 -C 6 alkenyl, C 2 -
  • R 12 is an optionally substituted C--C 6 alkyl, aryl or heteroaryl group each optionally substituted;
  • R 12 is an optionally substituted C--C 6 alkyl, aryl or heteroaryl group;
  • y and w are each 0 or an integer of 1 or 2 ;
  • R 13 is H or a C j -C j alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 - C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
  • R 1(1 and R 15 are each independently H, halogen or a C x - C ⁇ alkyl, aryl, heteroaryl or C.,-C 6 alkoxy group each optionally substituted;
  • R 16 is H, COR 29 or a C.-C 8 alkyl, C 2 -C 6 alkenyl, C 2
  • R 17 and R 29 are each independently H or a C.-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl , C 3 -C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
  • R 1B , R 19 , R 20 , R 21 , R 22 , R 26 , R 27 and R 28 are each independently H or an optionally substituted C ⁇ - C 6 alkyl group;
  • R 23 and R 2i are each independently H or a C--C 6 alkyl, aryl or heteroaryl group each optionally substituted; and
  • R 25 is an optionally substituted C 1 -C 6 alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
  • halogen designates Br, Cl, I or F
  • cycloheteroalkyl designates a C 5 -C 7 cycloalkyl ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, 0 or S and optionally containing one double bond.
  • Exemplary of the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein X x is NR, 0 or S and R is an optional substituent as described hereinbelow.
  • heteroaryl designates a 5- to 10-membered aromatic ring system containing 1, 2 or 3 heteroatoms, which may be the same or different, selected from N, 0 or S.
  • heteroaryl ring systems include pyrrolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinolinyl, isoguinolinyl, indolinyl, benzothienyl, benzofuranyl, benzisoxazolyl or the like.
  • haloalkyl designates a C n H 2n+1 group having from one to 2n+l halogen atoms which may be the same or different and the term haloalkoxy as used herein designates an OC n H 2n+1 group having from one to 2n+l halogen atoms which may be the same or different.
  • substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino , formyl, alkoxycarbonyl , carboxyl, alkanoyl, alkylthio, alkylsuphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl (eg heteroaryl or cycloheteroalkyl) or cycloalkyl groups, preferably halogen atoms or lower alkyl groups.
  • substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino,
  • substituents may be present .
  • this may be linear or branched and may contain up to 12 , preferably up to 6, more preferably up to 4 carbon atoms.
  • Pharmaceutically acceptable salts may be any acid addition salt formed by a compound of formula I and a pharmaceutically acceptable acid such as phosphoric, sulfuric, • hydrochloric, hydrobromic, citric, maleic, alonic, mandelic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like.
  • Compounds of the invention may exist as one or more stereoisomers .
  • the various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
  • the present invention comprises compounds of Formula I, the stereoisomers thereof and the pharmaceutically acceptable salts thereof .
  • the compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an opticaly active form.
  • Preferred compounds of the invention are those compounds of formula I wherein W is S0 2 or CO. Also preferred are those compounds of formula I wherein X is 0.
  • Another group of preferred compounds of the invention are those compounds of formula I wherein Y is CR 14 .
  • Further preferred compounds of the invention are those compounds of formula I wherein R 12 is an aryl or heteroaryl group each optionally substituted; and n is 1.
  • R 12 are aryl e.g., phenyl or naphthyl, or heteroaryl e.g., thienyl (such as thien-2-yl) or quinolyl (such as quinolin-8-yl) ; said aryl and heteroaryl groups being unsubstituted or optionally substituted by one or more (e.g., 1 to 3) substituents the same or different as described herein.
  • Such substituents include halo, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl of 1-6 carbon atoms, halo (C j -C 6 ) alkyl, (C.-C 6 ) alkoxy, halo(C ⁇ -
  • C 6 )alkoxy amino, (C,-C 6 ) alkylamino, di- (C--C 6 alkyl) amino, formyl, (C ⁇ -C 6 alkoxy) carbonyl, carboxyl, (C.-C alkanoyl, (Ci-C 8 ) alkylthio, (C--C 6 ) alkylsulphinyl, (C,-C 5 ) alkyl- sulphonyl, carbamoyl, (C--C 5 ) alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heteroaryl and cycloheteroalkyl or (C 3 - C 8 ) cycloalkyl groups.
  • Such optionally substituted groups for R 12 are also examples of aryl or heteroaryl for each of R r R 4 , R 13 , R 14 , R 1S , R 16 , R 17 , R 23 , R 24 , R 25 and R 29 .
  • More preferred compounds of the invention are those compounds of formula I having one or more, e.g. all, of the following values: W is S0 2 ; X is 0; and n is 1.
  • Another group of more preferred compounds of the invention are those compounds of formula I having one or more, e.g. all, of the following values: W is S0 2 ; X is O; Y is CR 14 ; n is 1; and p is 1.
  • R 2 and R 3 are hydrogen.
  • An example of m is 0.
  • R s -R ⁇ m Y a ll f° r example be hydrogen.
  • This invention also provides a process for the preparation of a compound of formula I which comprises one of the following:
  • R 12 is as defined above and W is S0 2 , CO, CONH, CSNH or (CH 2 ) x ; said reactants protected on reactive sites and/or on reactive substituent groups as required, and removing any protecting groups, to give a corresponding compound of formula (I) ; or b) removing a protecting group from a compound of formula (C)
  • compounds of formula I wherein W is S0 2 ; X is 0; Y is CR 13 ; Z is CR 14 ; and R 4 and R ⁇ are H (la) may be prepared by reacting an hydroxyindole of formula II with an N-protected-2-methoxyheterocycle of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding indol-4- yloxyalkylheterocycle of formula IV. Subsequent sulfonylation and deprotection of the formula IV compound gives the desired formula la product .
  • the reaction sequence is illustrated in flow diagram I wherein P represents a protecting group.
  • Commonly used protecting groups include t-butyl- carboxylate, benzyl, acetyl, benzyloxycarbonyl, or any conventional group known to protect a basic nitrogen in standard synthetic procedures.
  • Compounds of formula I wherein W is S0 2 ; X is 0; Y is CH; Z is N and R 4 and R ⁇ 1 are H (lb) may be prepared by reacting a nitromethylphenol of formula V with an N- protected-2-alkoxyheterocyclic compound of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding heterocyclylalkoxybenzene of formula VI, reducing the nitro group of the formula VI compound, for example via catalytic hydrogenation, to give the amine of formula VII and reacting the formula VII amine with isoamylnitrite in the presence of potassium acetate and acetic anhydride to give the heterocyclyalkoxyindazole of formula VIII .
  • Compounds of formula I wherein X is S and W is S0 2 may be prepared by employing the appropriate indolylthiol or thiophenol and utilizing the reactions shown in flow diagrams I and II, respectively.
  • Compounds of formula I wherein W is CO may be prepared by reacting the benzazole precursor, for example a compound of formula IV, VIII, XIII or XV with the appropriate isocyanate, carbonyl halide or carbamoyl halide in the presence of a base.
  • compounds of formula I wherein W is (CH 2 ) X and x is an integer of 1, 2 or 3 may be prepared by reacting the appropriately substituted alkylhalide with a compound of formula IV, VIII, XIII or XV in the presence of a base.
  • Compounds of formula I wherein W is (CH 2 ) x and x is 0 may be prepared via a palladium-catalyzed N-arylation such as that descrited by D. W. Old et al , Organic Letters, 2000 (2) , pp 1403-1406. Using these and other conventional methods, compounds of formula I may be prepared from readily available starting materials.
  • the present invention provides a compound of formula XVI
  • X, Y, Z, m, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as defined for formula I .
  • Compounds of formula XVI are useful in the preparation of the therapeutic agents of formula I described hereinabove. Accordingly, the present invention also provides a method for the preparation of a compound of formula I wherein W is S0 2 (Ie) which comprises reacting a formula XVI compound with a sulfonyl chloride, R 12 S0 2 C1, wherein R 12 is as defined for formula I in the presence of a base optionally in the presence of a solvent. The reaction is shown in flow diagram V.
  • Bases suitable for use in the method of invention are strong bases such as NaH, KOt-Bu, or any conventional base capable of removing a proton from a basic indole or benzazole nitrogen atom.
  • the inventive compound of formula I may be utilized in the treatment of central nervous system disorders relating to or affected by the 5-HT6 receptor such as motor, mood, psychiatric, cognitive, neurodegenerative, or the like disorders, for example, Alzheimer's disease, Parkinson's disease, attention deficit disorder, anxiety, epilepsy, depression, obsessive compulsive disorder, migraine, sleep disorders, feeding disorders (such as anorexia or bulimia) , schizophrenia, memory loss, disorders associated with withdrawl from drug abuse, or the like or certain gastrointestinal disorders such as irritable bowel syndrome.
  • the present invention provides a method for the treatment of a disorder of the central nervous system (CNS) related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing said patient a therapeutically effective amount of a compound of formula I as described hereinabove.
  • the compounds may be provided by oral or parenteral administration or in any common manner known to be an effective administration of a therapeutic agent to a patient in need thereof .
  • the therapeutically effective amount provided in the treatment of a specific CNS disorder may vary according to the specific condition (s) being treated, the size, age and response pattern of the patient, the severity of the disorder, the judgment of the attending physician and the like.
  • effective amounts for daily oral administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg.
  • the compounds of the invention are provided by administering the compound or a precursor thereof in a solid or liquid form, either neat or in combination with one or more conventional pharmaceutical carriers or excipients. Accordingly, the present invention provides a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I as described hereinabove .
  • Solid carriers suitable for use in the composition of the invention include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating agents or encapsulating materials.
  • the carrier may be a finely divided solid which is in admixture with a finely divided compound of formula I.
  • the formula I compound may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Said powders and tablets may contain up to 99% by weight of the formula I compound.
  • Solid carriers suitable for use in the composition of the invention include calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Any pharmaceutically acceptable liquid carrier suitable for preparing solutions, suspensions, emulsions, syrups and elixirs may be employed in the composition of the invention.
  • Compounds of formula I may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof.
  • Said liquid composition may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo- regulators, or the like.
  • suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo- regulators, or the like.
  • suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo- regulators, or the like.
  • liquid carriers suitable for oral and parenteral administration include water (particularly containing additives as above, e.g.,
  • compositions of the invention which are sterile solutions or suspensions are suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions may also be administered intravenously.
  • Inventive compositions suitable for oral administration may be in either liquid or solid composition form.
  • N R designates nuclear magnetic resonance.
  • THF and EtOAc designate tetrahydrofuran and ethyl acetate, respectively.
  • the residue is purified by chromatography (silica gel, EtOAc :hexanes, 15:85).
  • the purified oil (5.05 g) is dissolved in ethanol, treated with 40% aqueous NaOH, heated at reflux temperature for 45 min, cooled in an ice-water bath, neutralized to pH 8 with concentrated HCl and concentrated in vacuo to remove the ethanol .
  • the resultant aqueous residue is extracted with EtOAc.
  • the combined extracts are washed sequentially with water and brine, dried over MgS0 4 and concentrated in vacuo to give a yellow oil.
  • the affinity of test compounds for the serotonin 5- HT6 receptor is evaluated in the following manner. Cultured Hela cells expressing human cloned 5-HT6 receptors are harvested and centrifuged at low speed (1,000 x g) for 10.0 min to remove the culture media. The harvested cells are suspended in half volume of fresh physiological phosphate buffered saline solution and recentrifuged at the same speed. This operation is repeated. The collected cells are then homogenized in ten volumes of 50 ⁇ i Tris.HCl (pH 7.4) and 0.5 mM EDTA. The homogenate is centrifuged at 40,000 x g for 30.0 min and the precipitate is collected.
  • the obtained pellet is resuspended in 10 volumes of Tris.HCl buffer and recentrifuged at the same speed.
  • the final pellet is suspended in a small volume of Tris.HCl buffer and the tissue protein content is determined in aliquots of 10-25 ⁇ l volumes.
  • Bovine Serum Albumin is used as the standard in the protein determination according to the method described in Lowry et al . , J. Biol. Chem. , 193:265 (1951) .
  • the volume of the suspended cell membranes is adjusted to give a tissue protein concentration of 1.0 mg/ml of suspension.
  • the prepared membrane suspension (10 times concentrated) is aliquoted in 1.0 ml volumes and stored at -70° C until used in subsequent binding experiments .
  • Binding experiments are performed in a 96 well microtiter plate format, in a total volume of 200 ⁇ l .
  • To each well is added the following mixture: 80.0 ⁇ l of incubation buffer made in 50 mM Tris.HCl buffer (pH 7.4) containing 10.0 mM MgCl 2 and 0.5 mM EDTA and 20 ⁇ l of [ 3 H] -LSD (S.A., 86.0 Ci/mmol, available from Amersham Life Science), 3.0 nM.
  • the dissociation constant, K-. of the [ 3 H]LSD at the human serotonin 5-HT6 receptor is 2.9 nM, as determined by saturation binding with increasing concentrations of [ 3 H]LSD.
  • the reaction is initiated by the final addition of 100.0 ⁇ l of tissue suspension. Nonspecific binding is measured in the presence of 10.0 ⁇ M methiothepin.
  • the test compounds are added in 20.0 ⁇ l volume .
  • the reaction is allowed to proceed in the dark for 120 min at room temperature, at which time, the bound ligand-receptor complex is filtered off on a 96 well unifilter with a Packard Filtermate ® 196 Harvester.
  • the bound complex caught on the filter disk is allowed to air dry and the radioactivity is measured in a Packard TopCount" equipped with six photomultiplier detectors, after the addition of 40.0 ⁇ l Microscint -20 scintillant to each shallow well.
  • the unifilter plate is heat-sealed and counted in a PackardTopCount with a tritium efficiency of 31.0%.
  • Specific binding to the 5-HT6 receptor is defined as the total radioactivity bound less the amount bound in the presence of lO.O ⁇ M unlabeled methiothepin. Binding in the presence of varying concentrations of test compound is expressed as a percentage of specific binding in the absence of test compound. The results are plotted as log % bound versus log concentration of test compound. Nonlinear regression analysis of data points with a computer assisted program Prism yielded both the IC 50 and the K £ values of test compounds with 95% confidence limits. A linear regression line of data points is plotted, from which the IC 50 value is determined and the K A value is determined based upon the following equation: where L is the concentration of the radioactive ligand used and K_.
  • the compounds of the present invention have a high degree of affinity for the 5-HT6 receptor.

Abstract

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

Description

HETEROCYCLYIA KOXY-, -ALKYLTHIO- AND -ALKYLAMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
This invention relates to heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5- hydroxytryptamine-6 ligands, to processes for preparing them, to methods of using them and to pharmaceutical compositions containing them.
BACKGROUND OF THE INVENTION
Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the neurotransmitter 5- hydroxytryptamine (5-HT) or serotonin. Serotonin is localized in the central and peripheral nervous systems and is known to affect many types of conditions including psychiatric disorders, motor activity, feeding behavior, sexual activity, and neuroendocrine regulation among others. The effects of serotonin are regulated by the various 5-HT receptor subtypes. Known 5-HT receptors include the 5-HTl family (e.g. 5-HTlA) , the 5-HT2 family (e.g. 5-HT2A) , 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 subtypes . The recently identified human 5-hydroxytryptamine-6 (5-HT6) receptor subtype has been cloned, and the extensive distribution of its mRNA has been reported. Highest levels of 5-HT6 receptor mRNA have been observed in the olfactory tubercle, the striatum, nucleus accumbens, dentate gyrus and CAl, CA2 and CA3 regions of the hippocampus. Lower levels of 5-HT6 receptor mRNA were seen in the granular layer of the cerebellum, several diencephalic nuclei, amygdala and in the cortex. Northern blots have revealed that 5-HT6 receptor mRNA appears to be exclusively present in the brain, with little evidence for its presence in peripheral tissues. The high affinity of a number of antipsychotic agents for the 5-HT6 receptor, in addition to its mRNA localization in striatum, olfactory tubercle and nucleus accumbens suggests that some of the clinical actions of these compounds may be mediated through this receptor. Therefore, 5-HT6 receptor ligands are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding disorders (e.g. anorexia and bulimia), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine and benzodiazepines) , schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome.
Therefore, it is an object of this invention to provide compounds which are useful as therapeutic agents in the treatment of a variety of central nervous system disorders related to or affected by the 5-HT6 receptor. It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
It is a feature of this invention that the compounds provided may also be used to further study and elucidate the 5-HT6 receptor. These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.
SUMMARY OF THE INVENTION
The present invention provides a compound of formula
Figure imgf000004_0001
(I) wherein W is S02, CO, CONH, CSNH or (CH2)χ;
X is 0, SOy or NR13; Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then Z must be CR15; m and x are each independently 0 or an integer of 1,
2 or 3; n and p are each independently an integer of 1, 2 or
3; R1 is halogen, CN, 0R16, C02R17, CONR18R19, CNR20NR21R22 , S02NR23R21, SOwR25, or a C.-C^lkyl, C2-C6alkenyl , C2-
C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted; R2, R3, R5, R6, R7, R8, R9, R10 and R1X are each independently H or an optionally substituted Cx- C6alkyl group; R, is H, CNR26NR27R28 or a C.,-C6alkyl, C2-C6alkenyl , C2- C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R12 is an optionally substituted C.-C6alkyl, aryl or heteroaryl grou ; y and w are each 0 or an integer of 1 or 2 ;
R13 is H or a C--C6alkyl, C2-C6alkenyl, C2-C6alkynyl , C3- C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R14 and R15 are each independently H, halogen or a C±- C6alkyl, aryl, heteroaryl or C--C6alkoxy group each optionally substituted; R16 is H, COR29 or a C.-C6alkyl, C2-C6alkenyl , C2- C6alkynyl, aryl or heteroaryl group each optionally substituted; R17 and R29 are each independently H or a C..-C6alkyl,
C2-C6alkenyl, C2-C6alkynyl , C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
■^•18 ' R_.9 ' ^-20 ' ^21 ' ^22 ' ^26 ' ^27 aI1 R.,8 alθ β C independently H or an optionally substituted Cx-
C6alkyl group; R23 and R24 are each independently H or a C--C6alkyl, aryl or heteroaryl group each optionally substituted; and R25 is an optionally substituted C.,-C6alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
The present invention also provides methods and compositions useful for the therapeutic treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
The present invention further provides a method for the preparation of compounds of formula I and a compound useful therefor.
DETAILED DESCRIPTION OF THE INVENTION
The 5-hydroxytryptamine-6 (5-HT6) receptor is one of the most recent receptors to be identified by molecular cloning. Its ability to bind a wide range of therapeutic compounds used in psychiatry, coupled with its intriguing distribution in the brain has stimulated significant interest in new compounds which are capable of interacting with or affecting said receptor. At present, there are no known fully selective agonists. Significant efforts are being made to understand the possible role of the 5-HT6 receptor in psychiatry, cognitive dysfunction, motor function and control, memory, mood and the like. To that end, compounds which demonstrate a binding affinity for the 5-HT6 receptor are earnestly sought both as an aid in the study of the 5-HT6 receptor and as potential therapeutic agents in the treatment of central nervous system disorders.
Surprisingly, it has now been found that heterocyclylalkoxy-, -thioxy- or -aminobenzazole derivatives of formula I demonstrate 5-HT6 affinity. Advantageously, said benzazole derivatives may be used as effective therapeutic agents for the treatment of central nervous system (CNS) disorders associated with or affected by the 5-HT6 receptor. Accordingly, the present invention provides heterocyclylalkoxy-, -alkylthio- or -alkylaminobenzazole derivatives of formula I
Figure imgf000007_0001
(I) wherein
W is S02, CO, CONH, CSNH or (CH2)x; X is 0, SOy or NR13; Y is CRM or N;
Z is CR1S or N with the proviso that when Y is N then
Z must be CR1S; m and x are each independently 0 or an integer of 1, 2 or 3; n and p are each independently an integer of 1, 2 or
3; R. is halogen, CN, OR16, C02R17, CONR18R19, CNR20NR21R22 ,
S02NR23R24, SOwR25, or a C.-C6alkyl, C2-C6alkenyl, C2- C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted; R2, R3, R5, R6, R7, R8, R9, R10 and Ru are each independently H or an optionally substituted C- C6alkyl group; R4 is H, CNR26NR27R28 or a C--C6alkyl, C2-C6alkenyl, C2-
C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R12 is an optionally substituted C--C6alkyl, aryl or heteroaryl group; y and w are each 0 or an integer of 1 or 2 ; R13 is H or a Cj-Cjalkyl, C2-C6alkenyl, C2-C6alkynyl, C3- C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R1(1 and R15 are each independently H, halogen or a Cx- Cβalkyl, aryl, heteroaryl or C.,-C6alkoxy group each optionally substituted; R16 is H, COR29 or a C.-C8alkyl, C2-C6alkenyl, C2- C6alkynyl,, aryl or heteroaryl group each optionally substituted;
R17 and R29 are each independently H or a C.-C6alkyl, C2-C6alkenyl, C2-C6alkynyl , C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R1B, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted Cα- C6alkyl group; R23 and R2i are each independently H or a C--C6alkyl, aryl or heteroaryl group each optionally substituted; and
R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof. As used in the specification and claims, the term halogen designates Br, Cl, I or F and the term cycloheteroalkyl designates a C5-C7cycloalkyl ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, 0 or S and optionally containing one double bond. Exemplary of the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein Xx is NR, 0 or S and R is an optional substituent as described hereinbelow.
Figure imgf000009_0001
Similarly, as used in the specification and claims, the term heteroaryl designates a 5- to 10-membered aromatic ring system containing 1, 2 or 3 heteroatoms, which may be the same or different, selected from N, 0 or S. Such heteroaryl ring systems include pyrrolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinolinyl, isoguinolinyl, indolinyl, benzothienyl, benzofuranyl, benzisoxazolyl or the like. The term haloalkyl as used herein designates a CnH2n+1 group having from one to 2n+l halogen atoms which may be the same or different and the term haloalkoxy as used herein designates an OCnH2n+1 group having from one to 2n+l halogen atoms which may be the same or different.
In the specification and claims, when the terms C1-C6alkyl/ C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl are designated as being optionally substituted, the substituent groups which are optionally present may be one or more of those customarily employed in the development of pharmaceutical compounds or the modification of such compounds to influence their structure/activity, persistence, absorption, stability or other beneficial property. Specific examples of such substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino , formyl, alkoxycarbonyl , carboxyl, alkanoyl, alkylthio, alkylsuphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl (eg heteroaryl or cycloheteroalkyl) or cycloalkyl groups, preferably halogen atoms or lower alkyl groups. Typically, 0-3 substituents may be present . When any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12 , preferably up to 6, more preferably up to 4 carbon atoms.
Pharmaceutically acceptable salts may be any acid addition salt formed by a compound of formula I and a pharmaceutically acceptable acid such as phosphoric, sulfuric, • hydrochloric, hydrobromic, citric, maleic, alonic, mandelic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like. Compounds of the invention may exist as one or more stereoisomers . The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active or may exhibit beneficial effects when enriched relative to the other stereoisomer (s) or when separated from the other stereoisomer (s) . Additionally, the skilled artisan knows how to separate, enrich or selectively prepare said stereoisomers. Accordingly, the present invention comprises compounds of Formula I, the stereoisomers thereof and the pharmaceutically acceptable salts thereof . The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an opticaly active form. Preferred compounds of the invention are those compounds of formula I wherein W is S02 or CO. Also preferred are those compounds of formula I wherein X is 0. Another group of preferred compounds of the invention, are those compounds of formula I wherein Y is CR14. Further preferred compounds of the invention are those compounds of formula I wherein R12 is an aryl or heteroaryl group each optionally substituted; and n is 1. Examples of R12 are aryl e.g., phenyl or naphthyl, or heteroaryl e.g., thienyl (such as thien-2-yl) or quinolyl (such as quinolin-8-yl) ; said aryl and heteroaryl groups being unsubstituted or optionally substituted by one or more (e.g., 1 to 3) substituents the same or different as described herein. Such substituents include halo, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl of 1-6 carbon atoms, halo (Cj-C6) alkyl, (C.-C6) alkoxy, halo(Cα-
C6)alkoxy, amino, (C,-C6) alkylamino, di- (C--C6alkyl) amino, formyl, (Cα-C6alkoxy) carbonyl, carboxyl, (C.-C alkanoyl, (Ci-C8) alkylthio, (C--C6) alkylsulphinyl, (C,-C5) alkyl- sulphonyl, carbamoyl, (C--C5) alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heteroaryl and cycloheteroalkyl or (C3- C8) cycloalkyl groups. Such optionally substituted groups for R12 are also examples of aryl or heteroaryl for each of R r R4, R13, R14, R1S, R16, R17, R23, R24, R25 and R29.
More preferred compounds of the invention are those compounds of formula I having one or more, e.g. all, of the following values: W is S02; X is 0; and n is 1. Another group of more preferred compounds of the invention are those compounds of formula I having one or more, e.g. all, of the following values: W is S02; X is O; Y is CR14; n is 1; and p is 1.
Examples of R2 and R3 are hydrogen. An example of m is 0. Rs-Rιι m Y all f°r example be hydrogen.
Among the preferred compounds of the invention are : 1- (phenylsulfonyl) -4- [ (2S) -pyrrolidin-2-ylmethoxy] -1H- indole ,-
1- [ (5-chlorothien-2-yl) sulfonyl] -4- [ (2S) -pyrrolidin-2- ylmethoxy] -iH-indole; 1- [ (2-fluorophenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -1H-indole; - [ (3-fluorophenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -IH-indole; - [ (4-fluorophenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -1H-indole; - [ (3, 4-dimethoxyphenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- yl ethoxy] -IH-indole; - ( {4- [2S) -pyrrolidin-2-ylmethoxy] -lH-indole-1- yl} sulfonyl) aniline; - (phenylsulfonyl) -4- [ (2R) -pyrrolidin-2-ylmethoxy] -1H- indole; - (phenylsulfonyl) -4- [ (2S) -pyrrolidin-2-ylmethoxy] -1H- indazole; - ( {4- [ (2S) -pyrrolidin-2-ylmethoxy] -lH-indazol-1- yl} sulfonyl) quinoline; - [ (2-chlorophenyl) sulfonyl] -4- [ (2S) -pyrrolidin-2- ylmethoxy] -lH-indazole; - [ (2-fluorophenyl) sulfonyl] -4- [ (2S) -pyrrolidin-2- ylmethoxy] -lH-indazole; - [ (5-chlorothien-2-yl) sulfonyl] -4- [ (2S) -pyrrolidin-2- ylmethoxy] -lH-indazole; - ( {4- [ (2S) -pyrrolidin-2-ylmethoxy} -lH-indazol-1- yl} sulfonyl) aniline; -chloro-4- ( {4- [ (2S) -pyrrolidin-2-ylmethoxy] -lH-indazol-
1-yl} sulfonyl) aniline; - (phenylsulfonyl) -4- (piperidin-2-ylmethoxy) -IH-indole; -{ [4- (piperidin-2-ylmethoxy) -lH-indol-1- yl] sulfonyl}aniline; - [ (2-fluorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) -
IH-indole; - [ (5-chlorothien-2-yl) sulfonyl] -4- (piperidin-2- ylmethoxy) -IH-indole; - [ (3-fluorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) -
1H-indole; - [ (2-fluorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) - lH-indazole; 1- [ (2-chlorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) -
IH-indazole; 1- [ (5-chlorothien-2-yl) sulfonyl] -4- (piperidin-2- ylmethoxy) -lH-indazole; 4- (azepan-2-ylmethoxy) -1- (phenylsulfonyl) -IH-indole; 4-{ [4- (azepan-2-ylmethoxy) -lH-indol-1- yl] sulfonyl}aniline; 4- (azepan-2-ylmethoxy) -1- [ (2-fluorophenyl) sulfonyl] -IH- indole; 4- (azepan-2-ylmethoxy) -1- [ (5-chlorothien-2-yl) sulfonyl] -
IH-indole; 4- (azepan-2-ylmethoxy) -1- [ (3-fluorophenyl) sulfonyl] -1H- indole; 4- (azepan-2-ylmethoxy) -1- [ (2-fluorophenyl) sulfonyl] -1H- indazole;
4- (azepan-2-ylmethoxy) -1- [ (2-chlorophenyl) sulfonyl] -1H- indazole; 4- (azepan-2-ylmethoxy) -1- [ (5-chlorothien-2-yl) sulfonyl] - lH-indazole; 1- (phenylsulfonyl) -5- (pyrrolidin-2-ylmethoxy) -IH-indole; 1- (phenylsulfonyl) -6- (pyrrolidin-2-ylmethoxy) -IH-indole; 1- (phenylsulfonyl) -5- (pyrrolidin-2-ylmethoxy) -1H- indazole; 1- (phenylsulfonyl) -6- (pyrrolidin-2-ylmethoxy) -1H- indazole; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
This invention also provides a process for the preparation of a compound of formula I which comprises one of the following:
a) reacting a compound of formula (B) :
Figure imgf000014_0001
wherein m, n, p, X, Y, Z, Rx, R2, R3, R5, R6, R7, R8, R9 R. and R are as defined herein, with an appropriate sulphonylating, acylating, carbamoylating, thiocarbamoylating, arylating or alkylating agent containing the group :
R12-W-
where R12 is as defined above and W is S02, CO, CONH, CSNH or (CH2)x ; said reactants protected on reactive sites and/or on reactive substituent groups as required, and removing any protecting groups, to give a corresponding compound of formula (I) ; or b) removing a protecting group from a compound of formula (C)
Figure imgf000014_0002
(I) (C) wherein m, n, p, W, X, Y, Z, Rx, R2, R3, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein and P is a protecting group to give a compound of formula (I) wherein R4 is H; or c) alkylating a compound of formula (I) as defined in claim 1 wherein R4 is hydrogen with an alkylating agent of formula R4-L wherein L is a leaving group, such as halogen, and R4 is as defined in claim 1 excepting hydrogen to give a corresponding compound of formula (I) ; or d) converting a compound of formula (I) having a reactive substituent group to a different compound of formula I; or e) converting a basic compound of formula (I) to an acid addition salt or vice versa.
Compounds of the invention may be conveniently prepared using conventional synthetic methods and, if required, standard separation and isolation techniques.
For example, compounds of formula I wherein W is S02; X is 0; Y is CR13; Z is CR14; and R4 and Rαι are H (la) may be prepared by reacting an hydroxyindole of formula II with an N-protected-2-methoxyheterocycle of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding indol-4- yloxyalkylheterocycle of formula IV. Subsequent sulfonylation and deprotection of the formula IV compound gives the desired formula la product . The reaction sequence is illustrated in flow diagram I wherein P represents a protecting group. Flow Diagram I
Figure imgf000016_0001
(H) (HI)
Figure imgf000016_0002
da) (IV)
Commonly used protecting groups include t-butyl- carboxylate, benzyl, acetyl, benzyloxycarbonyl, or any conventional group known to protect a basic nitrogen in standard synthetic procedures.
Compounds of formula I wherein W is S02; X is 0; Y is CH; Z is N and R4 and R±1 are H (lb) may be prepared by reacting a nitromethylphenol of formula V with an N- protected-2-alkoxyheterocyclic compound of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding heterocyclylalkoxybenzene of formula VI, reducing the nitro group of the formula VI compound, for example via catalytic hydrogenation, to give the amine of formula VII and reacting the formula VII amine with isoamylnitrite in the presence of potassium acetate and acetic anhydride to give the heterocyclyalkoxyindazole of formula VIII . Sulfonylation and deprotection of said formula VIII compound gives the desired compound of formula lb wherein R4 is H. Subsequent reaction of the formula lb compound with a suitable alkylating reagent such as an alkyl or aralkyl halide, R4-Hal, gives those compounds of formula lb' wherein R4 is other than H. The reaction sequence is shown in flow diagram II wherein P is a protecting group and Hal is Cl, Br or I.
Flow Diagram II
Figure imgf000018_0001
(VII) (VI)
Figure imgf000018_0002
(VIII) (lb)
Figure imgf000018_0003
(lb') Compounds of formula I wherein W is S02; X is NH; Y is CH; Z is N; and R4 and RX1 are H (Ic) may be prepared by the reductive amination of an N-protected carbonylalkylheterocyclic compound of formula X with a nitromethylaniline compound of formula IX to give the compound of formula XI, reducing the nitro group to give the amine of formula XII and reacting the formula XII amine with isoamylnitrite in the presence of potassium acetate and acetic anhydride to give the heterocyclylalkylamino-indazole of formula XIII.
Subsequent sulfonylation and deprotection as described hereinabove give the desired compound of formula Ic . The reaction sequence is shown in flow diagram III.
Flow Diagram III
Figure imgf000020_0001
(IX) (X)
Figure imgf000020_0002
(XII) (XI)
Figure imgf000020_0003
(Ic)
(XIII)
Similarly, compounds of formula I wherein W is S02; X ; Y is CR13; Z is CR14; and R4 and RX1 are H (Id) may be prepared by the reductive amination of the formula X carboxyaldehyde with an aminoindole of formula XIV to give the compound of formula XV. Subsequent sulfonylation and deprotection gives the desired product of formula Id. The reaction sequence is shown in flow diagram IV.
Flow Diagram IV
Figure imgf000021_0001
(X)
(XIV)
Figure imgf000021_0002
(Id) (XV)
Compounds of formula I wherein X is S and W is S02 may be prepared by employing the appropriate indolylthiol or thiophenol and utilizing the reactions shown in flow diagrams I and II, respectively. Compounds of formula I wherein W is CO may be prepared by reacting the benzazole precursor, for example a compound of formula IV, VIII, XIII or XV with the appropriate isocyanate, carbonyl halide or carbamoyl halide in the presence of a base. Similarly, compounds of formula I wherein W is (CH2)X and x is an integer of 1, 2 or 3 may be prepared by reacting the appropriately substituted alkylhalide with a compound of formula IV, VIII, XIII or XV in the presence of a base. Compounds of formula I wherein W is (CH2)x and x is 0 may be prepared via a palladium-catalyzed N-arylation such as that descrited by D. W. Old et al , Organic Letters, 2000 (2) , pp 1403-1406. Using these and other conventional methods, compounds of formula I may be prepared from readily available starting materials.
Advantageously, the present invention provides a compound of formula XVI
Figure imgf000022_0001
(XVI)
wherein X, Y, Z, m, n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined for formula I . Compounds of formula XVI are useful in the preparation of the therapeutic agents of formula I described hereinabove. Accordingly, the present invention also provides a method for the preparation of a compound of formula I wherein W is S02 (Ie) which comprises reacting a formula XVI compound with a sulfonyl chloride, R12S02C1, wherein R12 is as defined for formula I in the presence of a base optionally in the presence of a solvent. The reaction is shown in flow diagram V.
Flow Diagram V
Figure imgf000023_0001
(XVI) (Ie)
Bases suitable for use in the method of invention are strong bases such as NaH, KOt-Bu, or any conventional base capable of removing a proton from a basic indole or benzazole nitrogen atom.
Advantageously, the inventive compound of formula I may be utilized in the treatment of central nervous system disorders relating to or affected by the 5-HT6 receptor such as motor, mood, psychiatric, cognitive, neurodegenerative, or the like disorders, for example, Alzheimer's disease, Parkinson's disease, attention deficit disorder, anxiety, epilepsy, depression, obsessive compulsive disorder, migraine, sleep disorders, feeding disorders (such as anorexia or bulimia) , schizophrenia, memory loss, disorders associated with withdrawl from drug abuse, or the like or certain gastrointestinal disorders such as irritable bowel syndrome. Accordingly, the present invention provides a method for the treatment of a disorder of the central nervous system (CNS) related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing said patient a therapeutically effective amount of a compound of formula I as described hereinabove. The compounds may be provided by oral or parenteral administration or in any common manner known to be an effective administration of a therapeutic agent to a patient in need thereof .
The therapeutically effective amount provided in the treatment of a specific CNS disorder may vary according to the specific condition (s) being treated, the size, age and response pattern of the patient, the severity of the disorder, the judgment of the attending physician and the like. In general, effective amounts for daily oral administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg.
In actual practice, the compounds of the invention are provided by administering the compound or a precursor thereof in a solid or liquid form, either neat or in combination with one or more conventional pharmaceutical carriers or excipients. Accordingly, the present invention provides a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I as described hereinabove .
Solid carriers suitable for use in the composition of the invention include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating agents or encapsulating materials. In powders, the carrier may be a finely divided solid which is in admixture with a finely divided compound of formula I. In tablets, the formula I compound may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Said powders and tablets may contain up to 99% by weight of the formula I compound. Solid carriers suitable for use in the composition of the invention include calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. Any pharmaceutically acceptable liquid carrier suitable for preparing solutions, suspensions, emulsions, syrups and elixirs may be employed in the composition of the invention. Compounds of formula I may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof. Said liquid composition may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo- regulators, or the like. Examples of liquid carriers suitable for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution) , alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) or their derivatives, or oils (e.g., fractionated coconut oil and arachis oil) . For parenteral administration the carrier may also be an oily ester such as ethyl oleate or isopropyl myristate.
Compositions of the invention which are sterile solutions or suspensions are suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions may also be administered intravenously. Inventive compositions suitable for oral administration may be in either liquid or solid composition form.
For a more clear understanding, and in order to illustrate the invention more clearly, specific examples thereof are set forth hereinbelow. The following examples are merely illustrative and are not to be understood as limiting the scope and underlying principles of the invention in any way. Unless otherwise stated, all parts are parts by weight . The term N R designates nuclear magnetic resonance. The terms THF and EtOAc designate tetrahydrofuran and ethyl acetate, respectively.
EXAMPLE 1
Preparation of t-Butyl ( 2S) -2- [ ( lH-indol-4-yloxy)methyl] - 1-pyrrolidinecarbθ-gylate
Figure imgf000027_0001
A solution of 4-hydroxyindole (1.33 g, 10.0 mmol), (S) - (-) -1-t-butoxycarbonyl) -2-pyrrolidine methanol (4.02 g, 20.0 mmol) and triphenylphosphine (5.3 g, 20.0 mmol) in THF is treated with diethyl azodicarboxylate (3.2 mL, 20.0 mmol) under nitrogen at room temperature, stirred for 2 h at room temperature and concentrated in vacuo . The resultant residue is purified by flash chromatography (silica gel, EtOAc/hexane: 20/80) to give the title compound as a white solid, 1.5 g, mp 40-41 °C, identified by NMR and mass spectral analyses.
EXAMPLE 2 Preparation of t-Butyl (2S) -2- ({ [1- (phenylsulfonyl) -1H- indol- -yl] o_κy}methyl) -l-pyrrolidinecarboacylate
Figure imgf000028_0001
A stirred solution of t-butyl (2S) -2- [ (lH-indol-4- yloxy) methyl] -1-pyrrolidinecarboxylate (1.23 g, 3.89 mmol) in THF is treated with sodium hydride (0.17 g, 60% in mineral oil, 4.28 mmol) under nitrogen at room temperature, stirred for 30 minutes, treated with benzenesulfonyl chloride (0.55 mL, 4.28 mmol), stirred at room temperature for 22 h, quenched with ice-water and diluted with EtOAc . The organic phase is separated, washed sequentially with water and brine, dried over MgS04 and concentrated in vacuo . The resultant residue is purified by flash chromatography (siliga gel, EtOAc/hexanes, 2/8) to afford the title compound as an off-white foam, 1.21 g, mp 48-50 °C, identified by NMR and mass spectral analyses.
EXAMPLE 3
Preparation of 1- (Phenylsulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoacy] -IH-indole hvdrochloride
Figure imgf000029_0001
A solution of t-butyl (2S) -2- ( { [1-phenylsulfonyl) - lH-indol-4-yl] oxy}methyl) -1-pyrrolidinecarboxylate (1.06 g, 2.32 mmol) in methanol and HCl (11.6 mL IM in ether) is heated at 60 °C under nitrogen for 2h, cooled to room temperature and concentrated in vacuo . The resultant residue is treated with EtOAc and filtered. The filtercake is dried in vacuo to give the title compound as an off-white solid, 0.89 g, mp 194-196°C, identified by NMR and mass spectral analyses .
EXAMPLES 4 -9
Preparation of 1- (Arylsulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoKy] -IH-indole Hydrochloride
Figure imgf000030_0001
Using essentially the same procedure described in Examples 2 and 3 hereinabove and employing potassium t- butoxide and the appropriate arylsulfonyl chloride, the compounds shown in Table I are obtained and identified by NMR and mass spectral analyses.
Table I
Figure imgf000030_0002
Example mp No. R X °C
4 5-chlorothien-2-yl 1 204-206 5 2-fluorophenyl 1 153-155 Table I (cont'd)
Figure imgf000031_0001
Example mp
No. R„ X *C
6 3-fluorophenyl 1 160-162
7 4-fluorophenyl 1 258 (dec)
8 3 , 4-dimethoxyphenyl 1 115 (dec)
9 4-aminopheny1 2 150 (dec)
EXAMPLE 10
Preparation of t-Butvl (2R)-2- ■[(IH-indol- -4-vloxv)methyl] - pyrrolidine- -1-carboxvlate
Figure imgf000031_0002
A stirred solution of 4-hydroxyindole (1.33 g, 10.0 mmol) , (R) - (+) -1- (t-butoxycarbonyl) -2-pyrrolidinemethanol (4.02 g, 20.0 mmol) and triphenylphosphine (5.3 g, 20.0 mmol) in THF is treated with diethyl azodicarboxylate (3.2 mL, 20 mmol), stirred for 3 h at room temperature and concentrated in vacuo . The resultant residue is treated with EtOAc and filtered through a pad of silica gel. The filtrate is concentrated to give a residue which is purified by chromatography (silica gel, EtOAc:hexanes, 15:80) to afford the title compound as a white solid, 1.08 g, mp 146-147 °C; identified by NMR and mass spectral analyses.
EXAMPLE 11
Preparation of 1- (Pheny sulfonyl) -4- [ (2R) -pyrrolidin-2- yl ethoxy] -IH-indole hydrochloride
Figure imgf000032_0001
A solution of t-butyl (2R) -2- [ (lH-indol-4- yloxy)methyl]pyrrolidine-l-carboxylate (0.316 g, 1.0 mmol) in THF is treated with potassium t-butoxide (1.5 mL, 1.5 mmol, IM in THF) at room temperature, stirred for 3 min, treated with benzenesulfonyl chloride (0.264 g, 1.5 mmol), stirred for 6 h under nitrogen at room temperature, quenched with IN aqueous HCl and water and diluted with EtOAc . The organic phase is separated, washed sequentially with water and brine, dried over MgS04 and concentrated in vacuo . The resultant residue is treated with HCl (1.5 mL, IN in Et20) , heated at reflux temperature for 3 h, cooled to room temperature and filtered. The filtercake is air-dried to afford the title compound as an off-white solid, 0.24 g, mp 204- 206 °C, identified by NMR and mass spectral analyses.
EXAMPLE 12
Preparation of t-Butyl ( 2S) -2- [ (2- ■methvl-3- nitrophenoxv) methyl] pyrrolidine- -1- ■ carboxylate
Figure imgf000033_0001
A stirred solution of 2-methyl-3-nitrophenol (3.80 g, 24.84 mmol), (S) - (-) -1-tert-butoxycarbonyl) -2- pyrrolidinemethanol (5.0 g, 24.8 mmol) and triphenylphosphine (6.5 g, 24.8 mmol) in THF is treated with diethylazodicarboxylate (4.3 g, 24.8 mmol), stirred for 3 h at room temperature and concentrated in vacuo. The resultant residue is mixed with ether, stored at 0°C overnight and filtered. The filtrate is concentrated in vacuo to give a residue which is purified by chromatography (silica gel, EtOAc :hexanes, 20:80) to afford the title compound as a light yellow semisolid, 7.73 g, (91% yield), identified by NMR and mass spectral analyses . EXAMPLE 13
Preparation of t-Butyl (2S) -2- E (3-amino-2- methylphenoxy)methyl]pyrrolidine-l-carboχylate
Figure imgf000034_0001
A solution of t-butyl (2S) -2- [ (2-methyl-3- nitrophenoxy) methyl ]pyrrolidine-l-carboxylate (7.63 g, 21.9 mmol) and 10% Pd/C (0.38 g) in ethanol is hydrogenated (50 psi) at room temperature for 4 h and filtered. The filtrate is concentrated in vacuo to afford the title compound as an off-white solid, 6.66 g, mp 110 °C, identified by NMR and mass spectral analyses.
EXAMPLE 14
Preparation of t-Butyl (2S) -2- [ (lH-indazol-4- yloxy)methyl]pyrrolidine-1-carboxylate
Figure imgf000034_0002
A solution of t-butyl (2S) -2- [ (3-amino-2- ethylphenoxy) methyl ]pyrrolidine-l-carboxylate (5.00 g, 16.33 mmol), potassium acetate (1.92 g, 19.6 mmol) and acetic anhydride (4.9 mL, 52.3 mmol) in benzene is treated dropwise with isoamylnitrite (4.3 mL, 32.7 mmol), heated at reflux temperature overnight, cooled to room temperature and filtered. The filtercake is washed with benzene. The filtrates are combined and concentrated in vacuo to give a yellow oil residue. The residue is purified by chromatography (silica gel, EtOAc :hexanes, 15:85). The purified oil (5.05 g) is dissolved in ethanol, treated with 40% aqueous NaOH, heated at reflux temperature for 45 min, cooled in an ice-water bath, neutralized to pH 8 with concentrated HCl and concentrated in vacuo to remove the ethanol . The resultant aqueous residue is extracted with EtOAc. The combined extracts are washed sequentially with water and brine, dried over MgS04 and concentrated in vacuo to give a yellow oil. This oil is purified by chromatography (silica gel, EtOAc :hexanes, 30:70) to give the title product as an off-white solid, 3.52 g, mp 125 °C, identified by NMR and mass spectral analyses.
EXAMPLE 15
Preparation of 1- (Phenylsulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -IH-indazole trifluoroacetic acid salt
Figure imgf000035_0001
A solution of t-butyl (2S) -2- [ (lH-indazol-4- yloxy) methyl] pyrrolidine-1-carboxylate (0.317 g, 1.0 mmol) in dimethylformamide is treated with sodium hydride (0.08 g, 2.0 mmol, 60% in mineral oil) at room temperature, stirred for 10 min, treated with benzenesulfonyl chloride (0.264 g, 1.5 mmol), stirred for 18 h under nitrogen at room temperature, quenched with water and diluted with ether. The organic phase is separated, washed sequentially with water and brine, dried over MgS04 and concentrated in vacuo to give a white foam residue. The residue is purified by chromatography (silica gel, EtOAc :hexanes, 15:85) to give a white solid. This solid is dissolved in trifluoroacetic acid at 0°C, stirred at room temperature for 90 min and concentrated in vacuo . The resultant residue is triturated under ether to afford the title compound as a white solid, 300 mg, mp 218-219 °C, identified by NMR and mass spectral analyses .
EXAMPLES 16-21
Preparation of 1-Arylsulfonyl-4 [ (2S)- pyrrolidinylmethoxy] IH-indazole Hvdrochloride
Figure imgf000036_0001
Using essentially the same procedure described in Example 15 hereinabove and employing the appropriate arysulfonyl chloride and anhydrous HCl, the compounds in Table II are obtained and identified by NMR and mass spectral analyses . Table II
Figure imgf000037_0001
Example mp
No. R„ X 2C
16 8-quinolinyl 0 217-218
17 2-chlorophenyl 1 >255 (dec)
18 2-fluorophenyl 1 145-148
19 5-chlorothien-2- -yi 1 195
20 4-aminophenyl 2 150-155
21 4-amino-3-chlorophenyl 2 220 (dec)
EXAMPLE 22
Comparative Evaluation of 5-HT6 Binding Affinity of Test Compounds
The affinity of test compounds for the serotonin 5- HT6 receptor is evaluated in the following manner. Cultured Hela cells expressing human cloned 5-HT6 receptors are harvested and centrifuged at low speed (1,000 x g) for 10.0 min to remove the culture media. The harvested cells are suspended in half volume of fresh physiological phosphate buffered saline solution and recentrifuged at the same speed. This operation is repeated. The collected cells are then homogenized in ten volumes of 50 πi Tris.HCl (pH 7.4) and 0.5 mM EDTA. The homogenate is centrifuged at 40,000 x g for 30.0 min and the precipitate is collected. The obtained pellet is resuspended in 10 volumes of Tris.HCl buffer and recentrifuged at the same speed. The final pellet is suspended in a small volume of Tris.HCl buffer and the tissue protein content is determined in aliquots of 10-25 μl volumes. Bovine Serum Albumin is used as the standard in the protein determination according to the method described in Lowry et al . , J. Biol. Chem. , 193:265 (1951) . The volume of the suspended cell membranes is adjusted to give a tissue protein concentration of 1.0 mg/ml of suspension. The prepared membrane suspension (10 times concentrated) is aliquoted in 1.0 ml volumes and stored at -70° C until used in subsequent binding experiments .
Binding experiments are performed in a 96 well microtiter plate format, in a total volume of 200 μl . To each well is added the following mixture: 80.0 μl of incubation buffer made in 50 mM Tris.HCl buffer (pH 7.4) containing 10.0 mM MgCl2 and 0.5 mM EDTA and 20 μl of [3H] -LSD (S.A., 86.0 Ci/mmol, available from Amersham Life Science), 3.0 nM. The dissociation constant, K-. of the [3H]LSD at the human serotonin 5-HT6 receptor is 2.9 nM, as determined by saturation binding with increasing concentrations of [3H]LSD. The reaction is initiated by the final addition of 100.0 μl of tissue suspension. Nonspecific binding is measured in the presence of 10.0 μM methiothepin. The test compounds are added in 20.0 μl volume .
The reaction is allowed to proceed in the dark for 120 min at room temperature, at which time, the bound ligand-receptor complex is filtered off on a 96 well unifilter with a Packard Filtermate® 196 Harvester. The bound complex caught on the filter disk is allowed to air dry and the radioactivity is measured in a Packard TopCount" equipped with six photomultiplier detectors, after the addition of 40.0μl Microscint -20 scintillant to each shallow well. The unifilter plate is heat-sealed and counted in a PackardTopCount with a tritium efficiency of 31.0%.
Specific binding to the 5-HT6 receptor is defined as the total radioactivity bound less the amount bound in the presence of lO.OμM unlabeled methiothepin. Binding in the presence of varying concentrations of test compound is expressed as a percentage of specific binding in the absence of test compound. The results are plotted as log % bound versus log concentration of test compound. Nonlinear regression analysis of data points with a computer assisted program Prism yielded both the IC50 and the K£ values of test compounds with 95% confidence limits. A linear regression line of data points is plotted, from which the IC50 value is determined and the KA value is determined based upon the following equation:
Figure imgf000039_0001
where L is the concentration of the radioactive ligand used and K_. is the dissociation constant of the ligand for the receptor, both expressed in nM. Using this assay, the following Ki values are determined and compared to those values obtained by representative compounds known to demonstrate binding to the 5-HT6 receptor. The data are shown in Table III, below. Table i III
Test Compound 5- -HT6 Binding Ki
(Ex. No.) (nM)
3 6.0
4 7.0
5 2.0
6 8.0
7 31.0
8 95.0
9 1.0
11 106
15 7.0
16 85.0
17 5.0
18 8.0
19 5.0
20 9.0
21 16.0
5- -HT6 Binding Ki
Comparative Examples (nM)
Clozapine 6.0
Loxapine 41.4
Bromocriptine 23.0
Methiothepin 8.3
Mianserin 44.2
Olanzepine 19.5
As can be seen from the results set forth above, the compounds of the present invention have a high degree of affinity for the 5-HT6 receptor.

Claims

WHAT IS CLAIMED IS:
A compound of formula I
Figure imgf000041_0001
(I) wherein
W is S02, CO, CONH, CSNH or (CH2)x; X is O, SOy or NR13; Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then
Z must be CR1S; m and x are each independently 0 or an integer of 1, 2 or 3; n and p are each independently an integer of 1, 2 or
3; Rx is halogen, CN, OR16, C02R17, CONR18R19, CNR20NR21R22 ,
S02NR23R24, S0wR25, or a Cx-C6alkyl, C2-C6alkenyl, C2- C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted; R2, R3, R5, R6, R7, R8, R9, R10 and R1 are each independently H or an optionally substituted C- C alkyl group; R4 is H, CNR26NR27R2B or a C^C^lkyl , C2-C6alkenyl , C2- C6alkynyl , C3-C6cycloalkyl , cycloheteroalkyl , aryl or heteroaryl group each optionally substituted; R12 is an optionally substituted C--C6alkyl , aryl or heteroaryl group; y and w are each 0 or an integer of 1 or 2 ; R13 is H or a C..-C6alkyl , C2-C6alkenyl, C2-C6alkynyl , C3- C6cycloalkyl , cycloheteroalkyl , aryl or heteroaryl group each optionally substituted;
R14 and R15 are each independently H, halogen or a Cx- C6alkyl , aryl , heteroaryl or C1-C6alkoxy group each optionally substituted; R16 is H, COR29 or a C.-C6alkyl , C2-C6alkenyl , C2- C6alkynyl , aryl or heteroaryl group each optionally substituted; R17 and R29 are each independently H or a
Figure imgf000042_0001
, C2-C6alkenyl , C2-C6alkynyl , C3-C6cycloalkyl , cycloheteroalkyl , aryl or heteroaryl group each optionally substituted;
Rlβ, R19, R20, R21, R22 , R26, R27 and R28 are each independently H or an optionally substituted C.- C6alkyl group; R23 and R24 are each independently H or a Cj-Cjal yl , aryl or heteroaryl group each optionally substituted; and R25 is an optionally substituted C.-C6alkyl , aryl , or heteroaryl group; or a stereoisomer thereof or a pharmaceutically acceptable salt thereof .
2 . A compound according to claim 1 wherein W is
S0
3. A compound according to claim 1 or claim 2 wherein X is 0.
4. A compound according to any one of claims 1 to 3 wherein Y is CR14.
5. A compound according to any one of claims 1 to
4 wherein n is 1.
6. A compound according to any one of claims 1 to
5 wherein R12 is an aryl or heteroaryl group each optionally substituted.
7. A compound according to any one of claims 1 to 6 wherein R2 and R3 are both H.
8. A compound according to any one of claims 1 to 7 wherein p is 1.
9. A compound according to claim 1 selected from the group consisting of:
1- (phenylsulfonyl) -4- [ (2S) -pyrrolidin-2-ylmethoxy] -IH- indole,- 1- [ (5-chlorothien-2-yl) sulfonyl] -4- [ (2S) -pyrrolidin-2- ylmethoxy] -IH-indole;
1- [ (2-fluorophenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -iH-indole; 1- [ (3-fluorophenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -IH-indole; 1- [ (4-fluorophenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -IH-indole; 1- [ (3, 4-dimethoxyphenyl) sulfonyl) -4- [ (2S) -pyrrolidin-2- ylmethoxy] -IH-indole,- 4- ( {4- [2S) -pyrrolidin-2-ylmethoxy] -lH-indole-1- yl} sulfonyl) aniline; - (phenylsulf onyl) -4- [ (2R) -pyrrolidin-2 -ylmethoxy] -1H- indole; - (phenyl sulfonyl) -4- [ (2S) -pyrrolidin-2-ylmethoxy] -1H- indazole; - ( (4- [ (2S) -pyrrolidin-2-ylmethoxy] -lH-indazol-1- yl } sulf onyl) uinoline; - [ (2-chlorophenyl) sulfonyl] -4- [ (2S) -pyrrolidin-2 - ylmethoxy] -IH- indazole; - [ (2-f luorophenyl) sulfonyl] -4- [ (2S) -pyrrolidin-2 - ylmethoxy] -lH-indazole; - [ (5-chlorothien-2-yl) sulfonyl] -4- [ (2S) -pyrrolidin-2- ylmethoxy] -lH-indazole; - ( (4- [ (2S) -pyrrolidin-2-ylmethoxy}-lH-indazol-l- yl} sulfonyl) aniline; -chloro-4- ( {4- [ (2S) -pyrrolidin-2-ylmethoxy] -lH-indazol-
1-yl} sulfonyl) aniline; - (phenylsulfonyl) -4- (piperidin-2-ylmethoxy) -IH-indole; -{ [4- (piperidin-2-ylmethoxy) -lH-indol-1- yl] sulfonyl}aniline; - [ (2-fluorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) -
IH-indole,- - [ (5-chlorothien-2-yl) sulfonyl] -4- (piperidin-2- ylmethoxy) -IH-indole; - [ (3-fluorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) - IH-indole; - [ (2-fluorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) - lH-indazole; - [ (2-chlorophenyl) sulfonyl] -4- (piperidin-2-ylmethoxy) - lH-indazole; - [ (5-chlorothien-2-yl) sulfonyl] -4- (piperidin-2- ylmethoxy) -IH-indazole,• - (azepan-2-ylmethoxy) -1- (phenylsulfonyl) -IH-indole; -{ [4- (azepan-2-ylmethoxy) -lH-indol-1- yl] sulfonyl}aniline; 4- (azepan-2-ylmethoxy) -1- [ (2-fluorophenyl) sulfonyl] -1H- indole; 4- (azepan-2-ylmethoxy) -1- [ (5-chlorothien-2-yl) sulfonyl] -
IH-indole; 4- (azepan-2-ylmethoxy) -1- [ (3-fluorophenyl) sulfonyl] -IH- indole; 4- (azepan-2-ylmethoxy) -1- [ (2-fluorophenyl) sulfonyl] -1H- indazole; 4- (azepan-2-ylmethoxy) -1- [ (2-chlorophenyl) sulfonyl] -1H- indazole;
4- (azepan-2-ylmethoxy) -1- [ (5-chlorothien-2-yl) sulfonyl] -
IH-indazole; 1- (phenylsulfonyl) -5- (pyrrolidin-2-ylmethoxy) -IH-indole; 1- (phenylsulfonyl) -6- (pyrrolidin-2-ylmethoxy) -IH-indole; 1- (phenylsulfonyl) -5- (pyrrolidin-2-ylmethoxy) -1H- indazole; 1- (phenylsulfonyl) -6- (pyrrolidin-2-ylmethoxy) -1H- indazole; or a stereoisomer thereof; or a a pharmaceutically acceptable salt thereof .
10. A method for the treatment of a disorder of the central nervous system related to or affected by the 5- HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I as claimed in any one of claims 1 to 9 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof .
11. The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.
12. The method according to claim 10 wherein said disorder is schizophrenia or depression.
13. The method according to claim 11 wherein said disorder is Alzheimer's disease or Parkinson's diease.
14. The method according to claim 11 wherein said disorder is attention deficit disorder.
15. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of formula I as claimed in any one of claims 1 to 9 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
16. A process for the preparation of a compound of formula I which comprises one of the following:
b) reacting a compound of formula (B) :
Figure imgf000046_0001
wherein m, n, p, X, Y, Z, Rx, R2, R3, R5, R6, R7, R8, R9, R10 and Rαι are as defined herein, with an appropriate sulphonylating, acylating, carbamoylating, thiocarbamoylating, arylating or alkylating agent containing the group : R12- - where R12 is as defined above and W is S02, CO, CONH, CSNH or (CH2)X ; said reactants protected on reactive sites and/or on reactive substituent groups as required, and removing any protecting groups, to give a corresponding compound of formula (I) ;
or b) removing a protecting group from a compound of formula (C)
Figure imgf000047_0001
(I) (C)
wherein m, n, p, W, X, Y, Z, R1, R2, R3, R5, R6, R7, R8, R9, R10, RX1 and R12 are as defined herein and P is a protecting group to give a compound of formula (I) wherein R4 is H;
or c) alkylating a compound of formula (I) as defined in claim 1 wherein R4 is hydrogen with an alkylating agent of formula R4-L wherein L is a leaving group, such as halogen, and R4 is as defined in claim 1 excepting hydrogen to give a corresponding compound of formula (I) ;
or d) converting a compound of formula (I) having a reactive substituent group to a different compound of formula I ;
or
e) converting a basic compound of formula (I) to an acid addition salt or vice versa.
17. A process for the preparation of a compound of formula Ie
Figure imgf000048_0001
(fe) wherein X, Y, Z, , n, p, Rx, R2, R3, R4, R5, R6, R7, R8, R9,
R10, R1 and R12 are as defined in claim 1 which comprises reacting a compound of formula XVI
Figure imgf000049_0001
(XVI) wherein X, Y, Z, m, n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R1 axe as defined hereinabove with a sulfonyl chloride, R12S02C1, wherein R12 is as defined hereinabove in the presence of a base optionally in the presence of a solvent .
18. A compound of formula XVI
Figure imgf000049_0002
(XVI)
wherein
X is 0, S0y or NR13; Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then Z must be CR,C; m is 0 or an integer of 1, 2 or 3 ; n and p are each independently an integer of 1, 2 or
3; R^^ is halogen, CN, 0R16, C02R17, CONR18R19, CNR20NR21R22 , S02NR23R24, SOwR2S, or a C.-Cεalkyl, C2-C6alkenyl, C2-
C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted; R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted Cx-
C6alkyl group; R4 is H, CNR26NR27R28 or a C^-C8alkyl, C2-C6alkenyl, C2-
C6alkynyl, C3-C6cycloalkyl or cycloheteroalkyl group each optionally substituted; R13 is H or a C1-C6alkyl, C2-C6alkenyl , C2-C6alkynyl , C3-
C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R14 and R15 are each independently H, halogen or a Cx-
C6alkyl, aryl, heteroaryl or C.,-C6alkoxy group each optionally substituted;
R16 is H, COR29 or a C^^alkyl, C2-C6alkenyl, C2-
C6alkynyl , aryl or heteroaryl group each optionally substituted; R17 and R29 are each independently H or a C..-C6alkyl , C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C.- C6alkyl group;
R23 and R24 are each independently H or a C..-C6alkyl, aryl or heteroaryl group each optionally substituted; and R25 is an optionally substituted Cj-C^l yl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
19. A compound according to claim 18 wherein X is 0; Y is CR14; and n is 1.
20. A compound according to claim 18 or claim 19 wherein Z is CR15.
PCT/US2002/012512 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands WO2002085853A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
HU0303801A HUP0303801A2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
CA002444036A CA2444036A1 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
BR0209047-3A BR0209047A (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 binders
KR10-2003-7013584A KR20030088507A (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP02736592A EP1392682A2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EA200301143A EA200301143A1 (en) 2001-04-20 2002-04-19 DERIVATIVES OF HETEROCYCLILALKOXY-, ALKYLTIO-AND-ALKYLAMINOBENZENOLE AS 5-HYDROXITRIPTAMINE-6 LIGANDS
IL15844802A IL158448A0 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP2002583380A JP2004526781A (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptoamine-6 ligands
MXPA03009490A MXPA03009490A (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands.
AU2002309585A AU2002309585B2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
NO20034647A NO20034647L (en) 2001-04-20 2003-10-17 Hydroxyclylalkoxy, alkyloxy and alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28564401P 2001-04-20 2001-04-20
US60/285,644 2001-04-20

Publications (2)

Publication Number Publication Date
WO2002085853A2 true WO2002085853A2 (en) 2002-10-31
WO2002085853A3 WO2002085853A3 (en) 2002-12-19

Family

ID=23095117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/012512 WO2002085853A2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Country Status (17)

Country Link
US (2) US6831094B2 (en)
EP (1) EP1392682A2 (en)
JP (1) JP2004526781A (en)
KR (1) KR20030088507A (en)
CN (1) CN1293073C (en)
AR (1) AR034588A1 (en)
AU (1) AU2002309585B2 (en)
BR (1) BR0209047A (en)
CA (1) CA2444036A1 (en)
EA (1) EA200301143A1 (en)
HU (1) HUP0303801A2 (en)
IL (1) IL158448A0 (en)
MX (1) MXPA03009490A (en)
NO (1) NO20034647L (en)
PL (1) PL366639A1 (en)
WO (1) WO2002085853A2 (en)
ZA (1) ZA200309009B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104193A1 (en) * 2002-06-05 2003-12-18 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
WO2004050085A1 (en) * 2002-12-03 2004-06-17 F. Hoffmann-La Roche Ag Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
WO2005037834A1 (en) * 2003-10-20 2005-04-28 Biovitrum Ab NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS
WO2007142905A2 (en) * 2006-06-01 2007-12-13 Wyeth 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
US10392368B2 (en) 2017-08-01 2019-08-27 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008438A (en) * 2003-02-14 2005-10-19 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands.
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
JP2009504738A (en) * 2005-08-15 2009-02-05 ワイス Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007117413A1 (en) * 2006-04-05 2007-10-18 Wyeth Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US20090023925A1 (en) * 2007-06-28 2009-01-22 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
WO2011143430A1 (en) 2010-05-12 2011-11-17 Abbott Laboratories Indazole inhibitors of kinase
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003298A1 (en) * 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US6054469A (en) * 1995-11-16 2000-04-25 Merck Sharp & Dohme Ltd. Substituted tetrahydropyridine derivatives acting on 5-HT receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3835291A1 (en) 1988-04-19 1989-11-02 Bayer Ag 1,3-DISUBSTITUTED PYRROLIDINES
US5274097A (en) * 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
TW288010B (en) * 1992-03-05 1996-10-11 Pfizer
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH0940646A (en) 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd Condensed benzene ring derivative or its salt
WO1998050346A2 (en) * 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
AU5960300A (en) 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
EP1355904B1 (en) * 2000-12-22 2007-08-01 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
MXPA05008438A (en) * 2003-02-14 2005-10-19 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003298A1 (en) * 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US6054469A (en) * 1995-11-16 2000-04-25 Merck Sharp & Dohme Ltd. Substituted tetrahydropyridine derivatives acting on 5-HT receptors

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104193A1 (en) * 2002-06-05 2003-12-18 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
US6774241B2 (en) 2002-06-05 2004-08-10 Roche Palo Alto Llc 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof
WO2004050085A1 (en) * 2002-12-03 2004-06-17 F. Hoffmann-La Roche Ag Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
US7084169B2 (en) 2002-12-03 2006-08-01 Roche Palo Alto Llc Aminoalkoxyindoles and methods of use
KR100755580B1 (en) * 2002-12-03 2007-09-06 에프. 호프만-라 로슈 아게 Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AU2003289903B2 (en) * 2002-12-03 2008-06-26 F. Hoffmann-La Roche Ag Aminoalkoxyindoles as 5-HT6-receptor ligands for the treatment of CNS-disorders
WO2005037834A1 (en) * 2003-10-20 2005-04-28 Biovitrum Ab NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS
WO2007142905A2 (en) * 2006-06-01 2007-12-13 Wyeth 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
WO2007142905A3 (en) * 2006-06-01 2008-01-24 Wyeth Corp 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9872860B2 (en) 2010-10-06 2018-01-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8674090B2 (en) 2010-10-06 2014-03-18 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US9062003B2 (en) 2010-10-06 2015-06-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9156797B2 (en) 2010-10-06 2015-10-13 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10660898B2 (en) 2010-10-06 2020-05-26 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8541411B2 (en) 2010-10-06 2013-09-24 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10314845B2 (en) 2010-10-06 2019-06-11 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
US10392368B2 (en) 2017-08-01 2019-08-27 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
US10538513B2 (en) 2017-08-01 2020-01-21 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
US10968205B2 (en) 2017-08-01 2021-04-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
US11339160B2 (en) 2019-01-23 2022-05-24 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors

Also Published As

Publication number Publication date
EA200301143A1 (en) 2004-02-26
NO20034647D0 (en) 2003-10-17
IL158448A0 (en) 2004-05-12
PL366639A1 (en) 2005-02-07
CN1293073C (en) 2007-01-03
JP2004526781A (en) 2004-09-02
ZA200309009B (en) 2005-02-21
AR034588A1 (en) 2004-03-03
US6831094B2 (en) 2004-12-14
KR20030088507A (en) 2003-11-19
HUP0303801A2 (en) 2004-03-01
BR0209047A (en) 2004-08-10
US20050065185A1 (en) 2005-03-24
CA2444036A1 (en) 2002-10-31
AU2002309585B2 (en) 2008-01-31
US20030078286A1 (en) 2003-04-24
EP1392682A2 (en) 2004-03-03
NO20034647L (en) 2003-11-20
WO2002085853A3 (en) 2002-12-19
CN1518548A (en) 2004-08-04
MXPA03009490A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
US6815456B2 (en) Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6509357B1 (en) 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6831094B2 (en) Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1355900B1 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
AU2002309585A1 (en) Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
KR20030040566A (en) 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002251811A1 (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP2006518385A (en) Heterocyclyl-3-sulfonylindazole as 5-hydroxytryptamine-6 ligand
US7541358B2 (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
AU2002307424A1 (en) Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytrypltamine-6 ligands
US20030225121A1 (en) Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands
AU2008203389A1 (en) Heterocyclyloxy-, -thioxy- and - aminobenzazole derivatives as 5- hydroxytryptamine-6 ligands
AU2002245102A1 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002736592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002309585

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1298/KOLNP/2003

Country of ref document: IN

Ref document number: 01298/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 528915

Country of ref document: NZ

Ref document number: 2444036

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009490

Country of ref document: MX

Ref document number: 158448

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020037013584

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002583380

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/09009

Country of ref document: ZA

Ref document number: 200309009

Country of ref document: ZA

Ref document number: 200301143

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 028123409

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002736592

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642